Cardiac Reprogramming Overview

Principles

Definition

Cardiac reprogramming is a research field and methodological approach focused on converting non-cardiac cell types directly into functional cardiomyocytes or cardiomyocyte progenitors. This process, often achieved through the introduction of specific transcription factors or other molecular cues, represents a significant strategy in regenerative medicine for potentially repairing damaged heart tissue by generating new cardiac cells in situ or ex vivo.

Ontological type

Core Mechanisms

Therapeutic Applications

Experimental Protocols

Key developments

Key Figures

Cardiac Transcriptional Blueprint era

Eric N. Olson, affiliated with Harvard University and The University of Texas Southwestern Medical Center in this era, helped define the cardiac transcriptional blueprint that orchestrated chamber- and lineage-specific programs. His work identified the essential roles of GATA4 in heart tube formation and ventral morphogenesis and highlighted Hand1-related mesodermal defects as key readouts of cardiac development in this era. Joseph Itskovitz-Eldor, with affiliations at Harvard University and the Massachusetts Institute of Technology during this period, contributed to the era by advancing human embryonic stem cell–cardiac lineage concepts. The 2001 study reported that human embryonic stem cells can differentiate into cardiomyocyte-like myocytes with structural and functional properties, reinforcing hESCs as a platform for cardiac fate specification in the transcriptional blueprint era. [1][3][4][6][7][2][3][5][8]

Direct Reprogramming Paradigm era

Kenneth R. Chien [1], with appointments at Harvard University [3] and the University of California, San Francisco [4], was a central figure in the Direct Reprogramming Paradigm era. His contributions in this era include the study Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages [6], and Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart [7], findings that highlighted developmental origins and lineage plasticity as essential foundations for direct reprogramming. Charles E. Murry [2], with appointments at Harvard University [3] and Washington University in St. Louis [5], was a leading figure in this era. His notable contribution includes Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts [8], which provided a model for functional maturation and therapeutic relevance in cardiac regeneration strategies during the Direct Reprogramming Paradigm.

Maturation-Integrated Regeneration era

Gordon Keller [1] emerged as a foundational figure in this era, with affiliations at Icahn School of Medicine at Mount Sinai [3] and the University of Hong Kong [4]. His key contributions include Stage-Specific Optimization of Activin/Nodal and BMP Signaling Promotes Cardiac Differentiation of Mouse and Human Pluripotent Stem Cell Lines [7], Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming [8], and SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells [9], collectively advancing reliable generation and purification of cardiomyocytes and laying groundwork for maturation and scalable production in this era. Joseph C. Wu [2] is affiliated with Stanford University [5] and the Albert Einstein College of Medicine [6] during this era. His contributions include Chemically defined generation of human cardiomyocytes [10] and Production of De Novo Cardiomyocytes: Human Pluripotent Stem Cell Differentiation and Direct Reprogramming [8], enabling reproducible, defined culture conditions and scalable production that underpin maturation and functional integration essential for translation.